News | July 10, 2023
Novavax's Nuvaxovid receives full marketing authorization in the EU
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
_256_384.jpg)
The collaboration aims to raise awareness about eye cancer, provide medical and surgical treatment support to children and supply nutritional supplements to aid in their faster recovery.
With close to 30-40 basic screening tests available, the unit encompasses all the essential parameters typically covered in annual health check-ups
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Investment will help fuel international partnerships, grow IGX Platform functionality, and diversify proposition with new generative AI solutions
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Rapid card test kits for iScreen malaria card antigen (Pf/Pv) & iScreen dengue NS1
Subscribe To Our Newsletter & Stay Updated
